Bleeding Patterns During Prophylaxis with a Full-Length Pegylated Recombinant Factor VIII (Bax 855) with Extended Half-Life in Hemophilia A

被引：0
|
作者：
Konkle, B. A. [1 ,2 ]
Stasyshn, O. [3 ]
Wynn, T. T. [4 ]
Manco-Johnson, M. J. [5 ]
Gruppo, R. [6 ]
Chowdary, P. [7 ,8 ]
Komrska, V. [9 ]
Griskevicius, L. [10 ]
Eyster, M. E. [11 ]
Chojnowski, K. [12 ]
Engl, W. [13 ]
Patrone, L. [14 ]
Abbuehl, B. [13 ]
机构：
[1] Bloodworks Northwest, Seattle, WA USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Ukraine Acad Med Sci, Lvov, Ukraine
[4] Univ Florida, Coll Med, Gainesville, FL USA
[5] Univ Colorado, Sch Med, Aurora, CO USA
[6] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA
[7] Royal Free Hosp, KD Haemophilia Ctr, Pond St, London NW3 2QG, England
[8] Royal Free Hosp, Thrombosis Unit, Pond St, London NW3 2QG, England
[9] Univ Hosp Motol, Prague, Czech Republic
[10] Vilnius Univ Hosp Santariskiu Klinikos, Vilnius, Lithuania
[11] Penn State Hershey Med Ctr, Hershey, PA USA
[12] Med Univ Lodz, Lodz, Poland
[13] Baxalta Innovat GmbH, Vienna, Austria
[14] Baxalta US Inc, Westlake Village, CA USA
来源：
HAEMOPHILIA | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P128
引用
收藏
页码：99 / 100
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients
    Brand, B.
    Gruppo, R.
    Wynn, T. T.
    Griskevicius, L.
    Fernandez, M. F. Lopez
    Chapman, M.
    Dvorak, T.
    Pavlova, B. G.
    Abbuehl, B. E.
    HAEMOPHILIA, 2016, 22 (04) : E251 - E258
  • [22] Clearance receptor interaction and half-life prolongation of pegylated recombinant full-length factor VIII in mice
    Schrenk, G.
    Schiviz, A.
    Knappe, S.
    Bauer, A.
    Gritsch, H.
    Billwein, M.
    Michaela, S.
    Turecek, P.
    Dockal, M.
    Putz, M.
    Hoellriegl, W.
    Scheiflinger, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 823 - 824
  • [23] Comparison of annual bleeding rates in subjects with severe hemophilia a receiving prophylaxis treatment with recombinant factor VIII or pegylated recombinant factor VIII (BAX 855)
    Engl, W.
    Abbuehl, B.
    Wolfsegger, M.
    Pavlova, B.
    Ewenstein, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 843 - 844
  • [24] Safety of PEG, PEG conjugates and pegylated recombinant human full-length coagulation factor VIII (BAX 855)
    Stidl, R.
    Fuchs, S.
    Bossard, M.
    Siekmann, J.
    Putz, M.
    Turecek, P. L.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 824 - 824
  • [25] Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis - new insight provided by pharmacokinetic modelling
    Gringeri, A.
    Wolfsegger, M.
    Steinitz, K. N.
    Reininger, A. J.
    HAEMOPHILIA, 2015, 21 (03) : 300 - 306
  • [26] Results of A Pivotal Clinical Trial Evaluating A Full-Length Pegylated Recombinant Factor VIII (Peg-RFVIII) with Extended Half-Life in Haemophilia A
    Konkle, B.
    Stasyshn, O.
    Wynn, T. T.
    Manco-Johnson, M. J.
    Gruppo, R. A.
    Tran, H.
    Komrska, V.
    Griskevicius, L.
    Eyster, M. E.
    Chojnowski, K.
    Engl, W.
    Patrone, L.
    Abbuehl, B.
    HAEMOPHILIA, 2015, 21 : 30 - 31
  • [27] Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations
    Nogami, Keiji
    Shima, Midori
    Fukutake, Katsuyuki
    Fujii, Teruhisa
    Taki, Masashi
    Matsushita, Tadashi
    Higasa, Satoshi
    Sato, Tetsuji
    Sakai, Michio
    Arai, Morio
    Uchikawa, Haruhiko
    Engl, Werner
    Abbuehl, Brigitt
    Konkle, Barbara A.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (05) : 704 - 710
  • [28] Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations
    Keiji Nogami
    Midori Shima
    Katsuyuki Fukutake
    Teruhisa Fujii
    Masashi Taki
    Tadashi Matsushita
    Satoshi Higasa
    Tetsuji Sato
    Michio Sakai
    Morio Arai
    Haruhiko Uchikawa
    Werner Engl
    Brigitt Abbuehl
    Barbara A. Konkle
    International Journal of Hematology, 2017, 106 : 704 - 710
  • [29] Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates
    Stidl, R.
    Fuchs, S.
    Bossard, M.
    Siekmann, J.
    Turecek, P. L.
    Putz, M.
    HAEMOPHILIA, 2016, 22 (01) : 54 - 64
  • [30] Correction to: Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations
    Keiji Nogami
    Midori Shima
    Katsuyuki Fukutake
    Teruhisa Fujii
    Masashi Taki
    Tadashi Matsushita
    Satoshi Higasa
    Tetsuji Sato
    Michio Sakai
    Morio Arai
    Haruhiko Uchikawa
    Werner Engl
    Brigitt Abbuehl
    Barbara A. Konkle
    International Journal of Hematology, 2018, 107 : 123 - 124
12345